Prana Biotechnology Limited (NASDAQ: PRAN) said its lead compound in development for Parkinson's disease (PD), PBT434, had progressed successfully though ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE